In a jury trial in Marshall, Texas that concluded on Friday, April 8, Morrison & Foerster secured a complete victory for its client Seagen Inc. in patent litigation involving Seagen’s pioneering antibody-drug conjugate technology.
The jury in the U.S. District Court for the Eastern District of Texas found that Daiichi Sankyo willfully infringed Seagen’s patent (U.S. Patent No. 10,808,039) through sales of its Enhertu cancer treatment and held the patent not invalid. The jury awarded $41.8 million in damages—the entire amount Seagen requested.
The Morrison & Foerster trial team representing Seagen included Michael Jacobs, Matthew Chivvis, Bryan Wilson, Matthew Kreeger, Jayson Cohen, Sumaiya Sharmeen, Karl Johnston, Chris Han and Evelyn Chang.